A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples